Literature DB >> 11751511

Detection of isolated tumor cells in bone marrow in early-stage breast carcinoma patients: comparison with preoperative clinical parameters and primary tumor characteristics.

B Naume1, E Borgen, G Kvalheim, R Kåresen, H Qvist, T Sauer, T Kumar, J M Nesland.   

Abstract

UNLABELLED: PURPOSE/EXPERIMENTAL
DESIGN: The importance of detection of disseminated isolated tumor cells (ITCs) in bone marrow (BM) is still not settled. BM aspirates from 920 patients with primary breast cancer were analyzed for tumor cells by standardized direct immunocytochemical analysis (ICC) of 2 x 10(6) mononuclear cells (MNCs) using anticytokeratin monoclonal antibody (AE1/AE3). Samples (637) were analyzed by negative immunomagnetic enrichment (IMS) followed by ICC (10 x 10(6) MNCs). Analyses of the primary tumor specimens have been performed, including histomorphology, tumor-node-metastasis (TNM) staging, grading, and immunohistochemical analyses.
RESULTS: Of the patients with infiltrating carcinoma, 63% were node negative (N0) and 33%, node positive (N+). The results show the presence of tumor cells in 13.4% of the evaluable patients after direct ICC analysis. The presence of tumor cells correlated to the nodal- and tumor stage, showing BM positivity in 9.9% of the N0 cases and 20.6% in the N+ group (P < 0.0005), 11.2% of the stage T(1) were positive, and 15.0% and 22.6% were positive in the T(2) and T(3/4) groups, respectively (P = 0.013). No correlation between detection of ITC and detection of p53 and cathepsin D expression was found. Vascular invasion and c-erbB2 expression were associated with ITCs in BM (P = 0.045 and P = 0.024, respectively). Node-negative patients with estrogen receptor (ER)+ and/or progesterone receptor (PgR)+ tumors had lower frequency of ITCs than ER-/PgR- (P = 0.004). The use of negative IMS increased the frequency of positive BM by 63% (P < 0.0005).
CONCLUSIONS: The direct ICC detection of ITCs in BM correlated with primary tumor stage, nodal stage, vascular invasion, c-erbB2 expression, and ER/PgR status. Analysis of larger BM samples by negative IMS resulted in increased number of ITC-positive patients.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11751511

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  22 in total

1.  MicroRNA let-7b regulates genomic balance by targeting Aurora B kinase.

Authors:  Jenni Heidi Eveliina Mäki-Jouppila; Sofia Pruikkonen; Mahesh Balasaheb Tambe; Miriam Ragle Aure; Tuuli Halonen; Anna-Leena Salmela; Leena Laine; Anne-Lise Børresen-Dale; Marko Johannes Kallio
Journal:  Mol Oncol       Date:  2015-01-27       Impact factor: 6.603

2.  Chemokine receptor CXCR4 expression in breast cancer as a potential predictive marker of isolated tumor cells in bone marrow.

Authors:  Neslihan Cabioglu; Aysegul Sahin; Michele Doucet; Ekrem Yavuz; Abdullah Igci; Engin O Yildirim; Esin Aktas; Sema Bilgic; Bayram Kiran; Gunnur Deniz; Janet E Price
Journal:  Clin Exp Metastasis       Date:  2005       Impact factor: 5.150

Review 3.  Adjuvant Bisphosphonate Therapy in Postmenopausal Breast Cancer.

Authors:  Stephanie Strobl; Kerstin Wimmer; Ruth Exner; Yelena Devyatko; Michael Bolliger; Florian Fitzal; Michael Gnant
Journal:  Curr Treat Options Oncol       Date:  2018-03-12

4.  Inhibition of skeletal metastasis by ectopic ERalpha expression in ERalpha-negative human breast cancer cell lines.

Authors:  Abhik Bandyopadhyay; Long Wang; Shiau Hui Chin; Lu-Zhe Sun
Journal:  Neoplasia       Date:  2007-02       Impact factor: 5.715

5.  Inhibition of osteolytic bone metastasis by unfractionated heparin.

Authors:  Colin K Yee; Martin Butcher; Melec Zeadin; Jeffrey I Weitz; Stephen G Shaughnessy
Journal:  Clin Exp Metastasis       Date:  2008-09-24       Impact factor: 5.150

6.  Serum N-glycan analysis in breast cancer patients--Relation to tumour biology and clinical outcome.

Authors:  Vilde D Haakensen; Israel Steinfeld; Radka Saldova; Akram Asadi Shehni; Ilona Kifer; Bjørn Naume; Pauline M Rudd; Anne-Lise Børresen-Dale; Zohar Yakhini
Journal:  Mol Oncol       Date:  2015-08-19       Impact factor: 6.603

7.  Presence of bone marrow micrometastasis is associated with different recurrence risk within molecular subtypes of breast cancer.

Authors:  Bjørn Naume; Xi Zhao; Marit Synnestvedt; Elin Borgen; Hege Giercksky Russnes; Ole Christian Lingjaerde; Maria Strømberg; Gro Wiedswang; Gunnar Kvalheim; Rolf Kåresen; Jahn M Nesland; Anne-Lise Børresen-Dale; Therese Sørlie
Journal:  Mol Oncol       Date:  2007-04-04       Impact factor: 6.603

8.  Cytokeratin-positive cells in the bone marrow of breast cancer patients and noncancer donors.

Authors:  David N Krag; Roberto Kusminsky; Edward Manna; Donald Weaver; Seth P Harlow; Michael Covelli; Mary A Stanley; Laurence McCahill; Frank Ittleman; Bruce Leavitt; Martin Krag; Patricia Amarante
Journal:  Appl Immunohistochem Mol Morphol       Date:  2009-10

9.  Persistence of disseminated tumor cells after neoadjuvant treatment for locally advanced breast cancer predicts poor survival.

Authors:  Randi R Mathiesen; Elin Borgen; Anne Renolen; Erik Løkkevik; Jahn M Nesland; Gun Anker; Bjørn Ostenstad; Steinar Lundgren; Terje Risberg; Ingvil Mjaaland; Gunnar Kvalheim; Per Eystein Lønning; Bjørn Naume
Journal:  Breast Cancer Res       Date:  2012-08-14       Impact factor: 6.466

10.  Identifying in-trans process associated genes in breast cancer by integrated analysis of copy number and expression data.

Authors:  Miriam Ragle Aure; Israel Steinfeld; Lars Oliver Baumbusch; Knut Liestøl; Doron Lipson; Sandra Nyberg; Bjørn Naume; Kristine Kleivi Sahlberg; Vessela N Kristensen; Anne-Lise Børresen-Dale; Ole Christian Lingjærde; Zohar Yakhini
Journal:  PLoS One       Date:  2013-01-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.